Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 10Colorectal Neoplasms 3HER2-positive Gastric Cancer 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2 1Gastric Adenocarcinoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × disitamab vedotin × Gastrointestinal × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡